You are here: Industry Insights > Allergan

News List

Ironwood and Allergan settle Linzess patent litigation with Mylan pharmaceutical-technology
January 07, 2019
Ironwood Pharmaceuticals and Allergan have entered an agreement with Mylan Pharmaceuticals to settle patent litigations over generic versions of Linzess (linaclotide) medicine.....
Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation pharmafocusasia
January 04, 2019
Ironwood Pharmaceuticals, Inc. and Allergan plc announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. resolving patent litigations brought in.....
Editas bags $25M from Allergan as FDA signs off on human CRISPR trial fiercebiotech
January 03, 2019
After a year’s delay, Editas Medicine is finally back on track. The gene-editing biotech announced Friday the FDA has OK’d its IND application and that it will start enrolling patients in a phase 1/2 trial of ......
Teva hit with $6.3M retaliation verdict in age, anti-American discrimination suit fiercepharma
December 05, 2018
Only months after a judge ruled that Teva must face a lawsuit from former manager Stephen Middlebrooks alleging retaliation, age discrimination and anti-American bias, jurors ruled in favor of the plaintiff and ordered...
Allergan Announces FDA Acceptance of sNDA for AVYCAZ americanpharmaceuticalreview
November 29, 2018
Allergan announced the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam)
Allergan to file ubrogepant for migraine early next year pharmatimes
October 19, 2018
Allergan is gearing up to file its oral CGRP receptor ubrogepant in the US for the treatment of migraine, following the success and completion of two safety studies.
Allergan adds actor Scott Eastwood to Alzheimer's effort for even more celebrity firepower fiercepharma
September 30, 2018
Allergan already has a laundry list of celebrities backing its Alzheimer’s awareness push, but that didn’t stop it from adding one more this week.
FDA accepts Allergan’s Vraylar for review pharmatimes
September 29, 2018
The US Food and Drug Administration has accepted for review an application from Allergan to expand the scope of its antipsychotic Vraylar.
Allergan amps aesthetics advertising in bid to keep flagship Botox on top fiercepharma
September 25, 2018
Allergan wants to know—are you bo-curious? That’s its upcoming ad pitch to consumers, particularly millennials, using a provocative play on words to refer to potential customers’ curiosity about Botox.
Allergan, eyeing Asia for growth, pours $14.7M into first medical aesthetics center in China fiercepharma
September 21, 2018
Allergan’s ambition for its medical aesthetics business is to grow to about $8 billion in 2025 from $3.8 billion in 2017 sales, with a big chunk coming from Asia.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page